Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab

Amgen Inc. is going through a transformational time as many of its top-selling drugs are maturing and its latest potential blockbuster franchise tries to find a foothold in the market. While Prolia/Xgeva (denosumab) offers a lucrative lifeline for the big biotech, investors are getting anxious about the company’s future; pushing for a dividend and for clarity about its strategy.